

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WF000270**PATIENT ID: BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

i	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: CYANIDE FREE DETERMINATION	12.1	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.07	3.8 - 4.8	mi l /μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.50	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	211	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	36.4	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	89.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	29.7	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	33.2	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	14.3 High	11.6 - 14.0	%
MENTZER INDEX	21.9		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	11.0 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			0.4
NEUTROPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	57	40 - 80	%
LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	37	20 - 40	%
MONOCYTES	05	2 - 10	%



Dr. Akansha Jain Consultant Pathologist







View Repor



Page 1 Of 18



CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WF000270 PATIENT ID : BABIF040690251 CLIENT PATIENT ID: 012306040027

ABHA NO

AGE/SEX :33 Years Female DRAWN :04/06/2023 10:24:00 RECEIVED: 04/06/2023 10:56:48 REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS	01	1 - 6	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
BASOPHILS	00	0 - 2	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	2.56	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	1.66	1.0 - 3.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.22	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER			•
ABSOLUTE EOSINOPHIL COUNT	0.04	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER		3132 3123	
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
		0.02 0.10	3, µ2
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.5		

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading

to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

was DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR =

3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist** Page 2 Of 18









PATIENT NAME: BABITA SHARMA

CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WF000270**

REF. DOCTOR: SELF

PATIENT ID : BABIF040690251 CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 15 0 - 20 mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition."

Dr. Akansha Jain Consultant Pathologist





Page 3 Of 18

View Details

View Report



PATIENT NAME: BABITA SHARMA

CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF

ACCESSION NO: **0251WF000270**PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain Consultant Pathologist



Page 4 Of 18

View Details





CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WF000270**PATIENT ID: BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 81 74 - 99 mg/dL

METHOD: GLUCOSE OXIDASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 4.5 Non-diabetic: < 5.7 %

Pre-diabetics: 5.7 - 6.4
Diabetics: > or = 6.5
Therapeutic goals: < 7.0
Action suggested: > 8.0
(ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 82.5 < 116.0 mg/dL

METHOD : CALCULATED PARAMETER

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 104 70 - 140 mg/dL

METHOD: GLUCOSE OXIDASE

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL **257 High** < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: CHOLESTEROL OXIDASE

TRIGLYCERIDES 107 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High >/=500 Very High

METHOD: LIPASE/GPO-PAP NO CORRECTION

Dr. Akansha Jain Consultant Pathologist



Page 5 Of 18







CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WF000270**PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u>	Results	Biological Reference Interva	l Units
HDL CHOLESTEROL	41	< 40 Low >/=60 High	mg/dL
METHOD: DIRECT CLEARANCE METHOD			
CHOLESTEROL LDL	195 High	< 100 Optimal 100 - 129	mg/dL
		Near optimal/ above optimal	
		130 - 159 Borderline High	
		160 - 189 High	
		>/= 190 Very High	
NON HDL CHOLESTEROL	216 High	Desirable: Less than 130 Above Desirable: 130 - 159	mg/dL
		Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	
METHOD: CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN	21.4	= 30.0</td <td>mg/dL</td>	mg/dL
CHOL/HDL RATIO	6.3 High	3.3 - 4.4	
		Low Risk	
		4.5 - 7.0	
		Average Risk	
		7.1 - 11.0	
		Moderate Risk	
		> 11.0 High Risk	
LDL/UDL BATTO	4.8 High	_	
LDL/HDL RATIO	4.8 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderat	
		Risk	
		>6.0 High Risk	
		<u> </u>	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

-		125 C + 2 (120 C C C C C C C C C C C C C C C C C C C
	Risk Category	
	Extreme risk group	A.CAD with > 1 feature of high risk group
	-	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =
		50 mg/dl or polyvascular disease







Page 6 Of 18



View Report



CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WF000270**PATIENT ID: BABIF040690251

CLIENT PATIENT ID: 012306040027 ABHA NO : AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.		
	Familial Homozygous Hypercholesterolemia		
High Risk	1. Three major ASCVD risk factors. 2. Dia	abetes with 1 major risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >1	90 mg/dl 5. Extreme of a single risk factor. 6. Coronary	
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		3. Current Cigarette smoking or tobacco use	
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR $=$ 30)	< OR = 60)		
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

dL
dL
dL
•
0



Dr. Akansha Jain Consultant Pathologist





Page 7 Of 18











CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WF000270**PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

 AGE/SEX
 :33 Years
 Female

 DRAWN
 :04/06/2023
 10:24:00

 RECEIVED
 :04/06/2023
 10:56:48

 REPORTED
 :04/06/2023
 15:40:35

	i	i	
Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	49 High	0 - 31	U/L
ALKALINE PHOSPHATASE METHOD: AMP OPTIMISED TO IFCC 37° C	100	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC)	45 High 37° C	7 - 32	U/L
LACTATE DEHYDROGENASE	318	230 - 460	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: UREASE KINETIC	8	5.0 - 18.0	mg/dL
CREATININE, SERUM			
CREATININE METHOD: ALKALINE PICRATE NO DEPROTEINIZATION	0.92	0.6 - 1.2	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD: CALCULATED PARAMETER	8.70		
URIC ACID, SERUM			
URIC ACID METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE	5.1	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	8.1	6.4 - 8.3	g/dL

Dr. Akansha Jain Consultant Pathologist



Page 8 Of 18









98 - 107

PATIENT NAME: BABITA SHARMA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WF000270**PATIENT ID: BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

ALBUMIN, SERUM

ALBUMIN 4.6 High 3.8 - 4.4 g/dL METHOD: BROMOCRESOL GREEN

THE HOD I BROTTO GREED GREET

GLOBULIN

GLOBULIN 3.5 2.0 - 4.1 g/dL

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM

METHOD: ION-SELECTIVE ELECTRODE

POTASSIUM, SERUM

METHOD: ION-SELECTIVE ELECTRODE

4.32

3.6 - 5.0

mmol/L

106.5

METHOD: ION-SELECTIVE ELECTRODE

Interpretation(s)

CHLORIDE, SERUM

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors, chlorpropamide,carbamazepine,anti	periodic paralysis,trauma (transient).Drugs: Adrenergic agents,	nephropathy, porphyria, expansion of extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.

Dr. Akansha Jain Consultant Pathologist





Page 9 Of 18









mmol/L



PATIENT NAME: BABITA SHARMA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

1ATPUR 302017 9314660100

ACCESSION NO: 0251WF000270 PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO

AGE/SEX :33 Years Female DRAWN :04/06/2023 10:24:00 RECEIVED: 04/06/2023 10:56:48 REPORTED: 04/06/2023 15:40:35

Test Report Status Results Biological Reference Interval Units **Final**

Increased in: Dehydration Increased in: Massive hemolysis Increased in: Renal failure, nephrotic (excessivesweating, severe severe tissue damage, rhabdomyolysis, syndrome, RTA, dehydration, vomiting or diarrhea), diabetes acidosis, dehydration, renal failure, overtreatment with mellitus, diabetesinsipidus, Addison's disease, RTA type IV, saline, hyperparathyroidism, diabetes hyperaldosteronism, inadequate hyperkalemic familial periodic insipidus, metabolic acidosis from water intake. Drugs: steroids, paralysis. Drugs: potassium salts, diarrhea (Loss of HCO3-), respiratory licorice, or al contraceptives. potassium- sparing diuretics, NSAIDs, alkalosis, hyperadre no corticis m beta-blockers, ACE inhibitors, high-Drugs: acetazolamide, androgens, dose trimethoprim-sulfamethoxazole. hydrochlorothiazide, salicylates. Interferences: Severe lipemia or Interferences: Hemolysis of sample, Interferences: Test is helpful in hyperproteinemi, if sodium analysis delayed separation of serum, assessing normal and increased anion involves a dilution step can cause prolonged fist clenching during blood gap metabolic acidosis and in spurious results. The serum sodium drawing, and prolonged tourniquet distinguishing hypercalcemia due to falls about 1.6 mEq/L for each 100 placement. Very high WBC/PLT counts hyperparathyroidism (high serum may cause spurious. Plasma potassium mg/dL increase in blood glucose. chloride) from that due to malignancy (Normal serum chloride) levels are normal.

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days
- 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (Ó10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

recommended for detecting a hemoglobinopathy
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin
treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated







Page 10 Of 18





PATIENT NAME: BABITA SHARMA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

1ATPUR 302017 9314660100

ACCESSION NO: 0251WF000270 PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO

AGE/SEX :33 Years Female DRAWN :04/06/2023 10:24:00 RECEIVED: 04/06/2023 10:56:48

REPORTED: 04/06/2023 15:40:35

Test Report Status Results **Biological Reference Interval** Units **Final**

(indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin Higher-than-normal levels may be due to: Chronic inflammation or infection including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver Albumin constitutes about half of the blood serum protein Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain **Consultant Pathologist**



Page 11 Of 18

View Report



PATIENT NAME: BABITA SHARMA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WF000270**PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

APPEARANCE SLIGHTLY HAZY

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

METHOD: SODIUM NITROPRUSSIDE REACTION

PH	5.0	4./-/.5

METHOD: DOUBLE INDICATOR PRINCIPLE

 SPECIFIC GRAVITY
 1.020
 1.003 - 1.035

METHOD: IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NEGATIVE

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE

NOT DETECTED

NEGATIVE

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

BLOOD DETECTED (+) NOT DETECTED

METHOD: PEROCIDASE ANTI PEROXIDASE

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD: DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NOT DETECTED

NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE DETECTED (+) NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS 5 - 7 NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S)

8-10

0-5

/HPF

METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain Consultant Pathologist



Page 12 Of 18

View Details

View Repor









NOT DETECTED

MC-5333

PATIENT NAME: BABITA SHARMA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WF000270**PATIENT ID: BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
EPITHELIAL CELLS	10-15	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
BACTERIA	DETECTED (FEW)	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION			

NOT DETECTED

Interpretation(s)

YEAST

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind		
	of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary		
	tract infection and glomerular diseases		
Leukocytes			
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by		
	genital secretions		
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or		
	bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,		
	interaction with Bence-Jones protein		
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal		
	diseases		







Page 13 Of 18



View Report



CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WF000270**PATIENT ID: BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status Final Results Biological Reference Interval Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain Consultant Pathologist



Page 14 Of 18



View Report





PATIENT NAME: BABITA SHARMA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WF000270**PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status Final Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD

SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist





Page 15 Of 18



View Report



REF. DOCTOR: SELF

MC-5333

PATIENT NAME: BABITA SHARMA

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

COLOUR

ACCESSION NO : **0251WF000270**

PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

METHOD: GROSS EXAMINATION

SAMPLE NOT RECEIVED

Sighter Sparks

Dr. Abhishek Sharma Consultant Microbiologist





Page 16 Of 18

View Details









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WF000270**PATIENT ID : BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3 96.68 60.0 - 181.0 ng/dL

METHOD: CHEMILUMINESCENCE

T4 **12.40 High** 4.5 - 10.9 μg/dL

METHOD : CHEMILUMINESCENCE

TSH (ULTRASENSITIVE) 1.122 0.550 - 4.780 μΙU/mL

METHOD: CHEMILUMINESCENCE

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions			
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)			
					Post Thyroidectomy (4) Post Radio-Iodine treatment			
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid			
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto			
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical			
					inflammation, drugs like amphetamines, Iodine containing drug and			
					dopamine antagonist e.g. domperidone and other physiological reasons.			
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism			
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre			
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid			
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4			
					replacement therapy (7) First trimester of Pregnancy			
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism			







Page 17 Of 18



View Report







Biological Reference Interval

PATIENT NAME: BABITA SHARMA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

<u>Final</u>

JAIPUR 302017 9314660100

Test Report Status

ACCESSION NO: **0251WF000270**PATIENT ID: BABIF040690251

CLIENT PATIENT ID: 012306040027

ABHA NO :

Results

AGE/SEX :33 Years Female
DRAWN :04/06/2023 10:24:00
RECEIVED :04/06/2023 10:56:48
REPORTED :04/06/2023 15:40:35

Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor			
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism			
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness			
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies			

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

Dr. Akansha Jain Consultant Pathologist





Page 18 Of 18



View Report







Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

Name: Mrs. BABITA SHARMA

Age/Gender: 33 Y/Female Patient ID : 012306040027

BarcodeNo:10087656

Referred By: Self

Registration No: 59148

Registered

: 04/Jun/2023 10:24AM

Analysed

: 05/Jun/2023 10:36AM

Reported

: 05/Jun/2023 10:36AM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

partner

*** End Of Report ***

Page 1 of 1

Dr. Neera Mehta M.B.B.S.,D.M.R.D. RMCNO.005807/14853



Aakriti Labs



3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME BABITA. 51

MOB- 3785082572.

Are-33/7

RATINA CHOICA

NN < 6119

Pa alous. 6 Wellness 6 Martner

Ref -1.00.

-1-00

Colvur / mon?

frand. Curre. BE


Dr. RAKES

M.S. OPTH. B. OPTH

Aakriti Labs
56350 / MRS BABITA SHARMA / 33 Yrs / F/ Non Smoker
Heart Rate : 74 bpm / Tested On : 04-Jun-23 12.06.30 / HF 0.05 Hz - LF 100 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s / Refd By.: MEDIWHEEL

ECG







Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME	MS BABITA SHARMA MEDI WHEEL				AGE 33YRS		SEX	FEMALE		
REF BY					DATE	04/06/2023		REG NO	0	
	1		E	CHO	CARDIOGR	AM RI	PORT			
WINDO	N- POOF	R/ADEO		AND DESCRIPTION OF REAL PROPERTY.	Commence of the Commence of th					
MITRAL			NORN	11771 1177		TRICUSPID			NORMAL	
AORTIC				PULMONARY			NORMAL			
2D/M-M	IOD				Maria III	L				
IVSD mm				IVSS mm		12.	12.9 AOF		RTA mm	20.6
LVID mm	1	41.6			LVIS mm	25.	.7 LA n		nm	28.1
LVPWD r	nm	9.1			LVPWS mm	12.	2 EF%		T.	60%
CHAMBE	RS						ting to the same of the same o			
LA A			NORMAL		RA	RA		N	NORMAL	
LV		NORMAL		RV	RV		NORMAL			
PERICARDIUM NOR		MAL								
DOPPLE	R STUDY	MITRA	L	7			and the same of th	710	Print Billion	
PEAK VE	LOCITY I	m/s E/A		1.17	/0.79	PEA	K GRADIAN	IT Mm	Hg	2
MEAN VELOCITY m/s		and the second		ME	MEAN GRADIANT MmHg					
MVA cm2 (PLANITMETERY)				MV	MVA cm2 (PHT)		4			
MR T		TRACE		746			L.			
AORTIC		100		ONLY VILLEGA			***************************************		- T	
		1.48		17,000	PEAK GRADIANT MmHg					
MEAN VELOCITY m/s		400	MEAN GRADIANT MmH		nHg					
AR						1000		The same		
TRICUSP			- 1	1				-		Maria Maria
PEAK VELOCITY m/s 0.60			PEAK GRADIANT MmHg				PARTIES SE			
MEAN VELOCITY m/s			MICH	MEAN GRADIANT MmHg						

PASP mmHg

RVEDP mmHg

PEAK GRADIANT MmHg

MEAN GRADIANT MmHg

IMPRESSION

MEAN VELOCITY m/s

PULMONARY
PEAK VELOCITY m/s

TR

PR

NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION

1.55

MILD

- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- TRACE MR
- MILD PR
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL
- CONCLUSION: MILD PR, FAIR LV FUNCTION.

Cardiologist